Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. poc-cycle

PoC-Cycle

Innovative Molecular Diagnostics point-of-care device for MRSA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 PoC-Cycle project word cloud

Explore the words cloud of the PoC-Cycle project. It provides you a very rough idea of what is the project "PoC-Cycle" about.

diagnosis    accuracy    rapid    diagnostics    almost    pathogen    health    revised    patients    sensitivity    approx    17    complexity    prepares    yearly    million    negative    missing    validation    pilot    microarrays    tests    care    cycle    discuss    collection    area    optimized    handling    sensitive    biomarkers    diagnostic    multicentric    detection    ing    hospitals    format    nucleic    robustness    broad    multiplex    screening    usability    pcr    workflow    pathogens    feasibility    infections    turnover    technically    market    semiconductor    provides    routine    combination    poc    mrsa    freedom    microfluidic    significantly    tuberculosis    cartridge    device    version    efficient    business    acceptance    fast    checked    point    innovative    administration    platform    introducing    multiplexing    900    appropriate    safe    hpv    limited    few    spread    reduce    operate    acid    platforms    signatures    sequence    deaths    disposable    forecast    2015    experts    mostly    friz    interviewing    diagnose    variations    reg   

Project "PoC-Cycle" data sheet

The following table provides information about the project.

Coordinator		 FRIZ BIOCHEM GMBH 

Organization address
address: FLORIANSBOGEN 2-4
city: NEURIED
postcode: 82061
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.frizbiochem.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-09-01   to  2014-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRIZ BIOCHEM GMBH DE (NEURIED) coordinator 50˙000.00

Map

 Project objective

FRIZ has developed PoC-Cycle® platform- an innovative diagnostics device introducing efficient multiplex nucleic acid testing to the point-of-care. It provides a combination of accuracy and sensitivity, multiplexing, and optimized workflow from sample collection to diagnosis. Current diagnostics platforms are technically limited: On one side only few sequence signatures can be checked, on the other side, the analysis of these signatures are mostly considered in one sequence area only due to the high complexity in developing Multiplex-PCR, as well as missing process-robustness for routine administration. FRIZ implemented a multiplex analysis in disposable microfluidic cartridge format with integrated semiconductor based on microarrays for the rapid and sensitive detection of a broad range and number of biomarkers. Key market is the screening of MRSA, a pathogen with wide spread and growing negative impact to European patients and health care systems. Experts forecast the number of deaths will increase from 6,000 to approx. 17,000 in 2015. Main users of the device are hospitals as they require simple and safe handling as well as fast and reliable results. European market potential can be estimated with 900,000 tests per year resulting in a yearly turnover of almost two million €. The new diagnostic device will significantly reduce the number of infections. Moreover, it provides future business opportunities due to its general approach for diagnose further pathogens e.g. HPV or tuberculosis. Within the project, FRIZ aims to identify end-users for validation, discuss the handling and identify possible variations to enhance the usability and acceptance of the new system in phase 2. To find an appropriate partner for validation is also part of this feasibility study. In addition, FRIZ prepares a revised version of a “freedom-to-operate” analysis. A multicentric validation study is planned as well as interviewing end-users and built up a pilot production in phase 2.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POC-CYCLE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POC-CYCLE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More